Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
Globe Newswire•17/11/2026•16:15 ET
0
Key Highlights
- ➤13 evaluable participants showed stable MDS-UPDRS motor scores after 12 months of rexaceract
- ➤No new safety signals emerged during rexaceract’s nine-month Phase 1b extension
- ➤CSF GluSph responses differed between Parkinson’s disease and subsequently diagnosed MSA participant
- ➤GT-04686 improved motor, cognitive, and olfactory functions in a GBA1-PD mouse model
- ➤Gain expects to select GT-04686’s initial therapeutic indication by end of Q4 2026
Expert Statements
Gene Mack, President and Chief Executive Officer of Gain Therapeutics
“Seeing MDS-UPDRS scores remain stable after a full year of dosing with rexaceract is an important clinical milestone for Gain and reinforces the potential for a durable clinical benefit. We are particularly encouraged by the differences in GluSph response observed between patients with Parkinson’s disease (PD) and the patient with multiple system atrophy (MSA), which suggest that GluSph may serve as a disease-specific biomarker for Parkinson’s disease. We will build on this clinical data with additional biomarker analysis of GluSph taken from CSF samples at the conclusion of the Phase 1b extension, which we believe will provide further insights into the underlying biology of the disease and strengthen our understanding of rexaceract”
Gene Mack, President and Chief Executive Officer of Gain Therapeutics
“Together, these findings reinforce our conviction that rexaceract has the potential to move treatment beyond symptom management by addressing the underlying biology of Parkinson’s disease and ultimately become the backbone of the next generation of Parkinson’s disease treatments.”
Gene Mack, President and Chief Executive Officer of Gain Therapeutics
“We are also encouraged by the increasingly robust preclinical development dossier for GT-04686. We believe the data presented support further development of GT-04686 and we expect to select an initial therapeutic indication for our second allosteric modulator by the end of Q4 2026. We look forward to continuing expansion of our differentiated GCase-targeting platform with the potential to unlock multiple therapeutic opportunities.”
Joanne Taylor, Chief Scientific Officer of Gain Therapeutics
“Our proprietary Magellan™ drug discovery platform has enabled the identification of novel GCase allosteric modulators, which have demonstrated encouraging preclinical results in models of Parkinson’s disease. We believe the potential of GCase as a therapeutic target beyond Parkinson’s disease is evident and we are excited to advance the development of GT-04686 while continuing to leverage the Magellan™ platform to discover promising therapeutic candidates for other neurodegenerative and rare diseases.”
IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression among the 13 evaluable participants who completed 12 months of daily oral administration of rexaceract
Differential CSF GluSph response in participants with Parkinson’s disease and a participant later diagnosed with MSA support potential of CSF GluSph as a disease-specific biomarker
Get started
Create a free account to read the full story.
